Investing
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Published:
Last Updated:
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 505.84% and currently trading at $800.98.
The company has been around since 1876 and the stock didn’t go public until 1952 but in the last 4 years, Eli Lilly went from a $100 billion market capitalization to $740 billion today, which also makes it a potential stock split stock.
However, as investors, we care about the stock price years down the line and what Eli Lilly will do in the next 3 to 5 years and beyond.
That is why 24/7 Wall Street looks at projected revenue and net income to give you our best estimate of future stock prices from 2025 to 2030.
Other “experts” look at past growth rates and assign future stock prices to those past numbers. However, we will walk you through our assumptions and give you the key drivers we see propelling Eli Lilly’s stock in the future.
12/3/2024
Today’s stock market is seeing mixed results, but Eli Lilly is up 1.29% due to positive corporate news.
11/27/2024
Eli Lilly has been downgraded by Ersete Gropu from a “Buy” to a “Hold” rating. While Eli Lilly’s pipeline remains promising, the concern stems from a recent spike in the company’s inventory and receivables relative to sales.
11/26/2024
Eli Lilly’s stock is rising after a new proposal from President Joe Biden. The proposal suggests that Medicaid and Medicare should cover the cost of weight-loss drugs for patients, which could lead to increased demand for drugs like Mounjaro.
11/22/2024
The FDA is still evaluating the supply situation for Eli Lilly’s weight-loss drug, tirzepatide. They are reassessing their previous decision to remove it from the drug shortage list. Until the FDA makes a final decision, compounders of tirzepatide will not face regulatory action.
11/21/2024
Eli Lilly recently announced a new partnership with Laekna Therapeutics, a Hong Kong-based biotech firm. The partnership will work on advancing the development of LAE102, an antibody targeting the ActRIIA receptor, primarily aimed at treating obsesity.
11/20/2024
Eli Lilly and Verge Genomics have made great strides in their joint venture to combat amyotrophic lateral sclerosis (ALS). Leveraging Verge’s AI-powered CONVERGE platform, the partnership has successfully identified two promising drug targets for the debilitating neurodegenerative disease.
11/19/2024
The Canadian Drug Agency (CDA) has announced its final recommendation for Ebglyss. The CDA-AMC has determined that Ebglyss should not be covered by public drug plans (except in Quebec) for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents aged 12 and older. Eli Lilly, however, is unhappy with this decision, with representatives asserting the company will continue to fight for both public and private reimbursement in Canada.
11/18/2024
Eli Lilly’s experimental drug, muvalaplin, has demonstrated potential in reducing a specific type of cholesterol. Data presented at the American Heart Association meeting in Chicago revealed that the highest dose of the drug led to a 70% reduction in lipoprotein(a) (or Lp(a)) levels measured by a traditional blood test. A more specific test developed by Eli Lilly further showed an even more impressive reduction of nearly 86%.
11/15/2024
Eli Lilly is taking legal action against the Department of Health and Human Services. The lawsuit seeks a court order that will let the company reduce the discounts they give to hospitals for their drugs.
11/14/2024
Eli Lilly’s weight-loss drug, tirzepatide, has shown promising results in preventing diabetes. After three years of weekly injections, nearly 99% of patients remained diabetes-free. This suggests that for every nine patients treated with tirzepatide, one new case of diabetes could be prevented.
How did Eli Lilly’s stock price soar so much in the past few years? Let’s take a look at the numbers:
Share Price | Revenues* | Net Income* | |
2016 | $80.36 | $21.22 | $2.74 |
2017 | $77.55 | $19.94 | ($0.21) |
2018 | $122.13 | $21.49 | $3.23 |
2019 | $140.83 | $22.32 | $8.32 |
2020 | $206.46 | $24.54 | $6.19 |
2021 | $238.31 | $28.32 | $5.58 |
2022 | 329.07 | $28.54 | $6.25 |
2023 | $745.91 | $34.12 | $5.24 |
*Revenue and Net Income in Billions
Since 2016, Eli Lilly’s revenue grew by 60% but income grew by 91%. Typically you wouldn’t expect a company growing at its top line by 7% annually to see an 828% increase in share price, however, investor sentiment for the next line of drugs front ran the stock price.
For example, in 2016 Eli Lilly was trading 13 times the trailing 12 months earnings and the market has increased its valuation each year and currently trades at a 125 times earnings multiple.
This raises the valid question, is Eli Lilly overvalued or will future revenues make up for the expensive valuation?
The current Wall Street consensus 1-year price target of Eli Lilly stock is $1030.00, which is 28.59% higher than today’s price of $800.98. Of the 26 analysts covering Eli Lilly stock, the current rating is 1.67 or “Outperform” with 1-year price targets as high as $1,100 and as low as $540.00.
24/7 Wall Street sets its 1-year price target at $1,040. Taking a look at the sum of its parts, we see Eli Lilly’s vertices valued as follows:
Endocrinology | $735/ share |
Oncology | $122/ Share |
Cardiovascular | $4/ Share |
Neuroscience | $16/ Share |
Immunology | $38/ Share |
Others and Pipeline | $110/ Share |
Cash | $17/ Share |
Valuing Eli Lilly’s stock price for the coming years, we will take a look at expected revenue and net income and give our best estimate of the market value of the company by assigning a price-to-earnings multiple.
Revenue | Net Income | EPS | |
2025 | $52.8 | $17.29 | 19.11 |
2026 | $62.5 | $22.49 | 25.03 |
2027 | $70.87 | $27.12 | 30.39 |
2028 | $80.68 | $32.2 | 25.97 |
2029 | $87.99 | $36.45 | 40.58 |
2030 | $96.67 | $41.12 | 46.29 |
*Revenue and net income reported in billions
We expect Eli Lilly’s P/E ratio in 2025 to be 60 with an EPS of $19.11, resulting in a price target of $1140.00 This prediction is based on strong revenue growth of 18.37% to $52.80 billion and net income expansion to $17.29 billion, continuing the upward trajectory from previous years.
For 2026, we anticipate a P/E ratio of 50 with an EPS of $25.03, leading to a price target of $1250.00. This reflects significant revenue growth of 18.37% to $62.50 billion and an increase in net income to $22.49 billion, driving higher earnings per share.
Heading into 2027, we project the P/E ratio to remain at 50, with EPS increasing to $30.39. This results in a price target of $1520.00. Continued revenue growth of 13.39% to $70.87 billion and net income expansion to $27.12 billion justifies this substantial increase in stock price.
With an EPS of $25.97 and a P/E ratio of 50 in 2028, we forecast the stock price to be $1300.00. A slight dip in EPS growth is expected, but sustained strong performance in net income to $32.20 billion and revenue growth of 13.84% to $80.68 billion keeps the stock highly valued.
By 2029, we estimate Eli Lilly’s EPS to rise to $40.58, with the P/E ratio adjusting to 40. This gives us a price target of $1623.00. The continuous revenue growth of 9.06% to $87.99 billion and net income expansion to $36.45 billion supports this higher valuation.
Price Target: $1850.00
Upside: 130.97%
By 2030, we estimate Eli Lilly’s EPS to rise to $46.29, with the P/E ratio adjusting to 40. This gives us a price target of $1850.00. The continuous revenue growth of 9.86% to $96.67 billion and net income expansion to $41.12 billion supports this higher valuation.
Year | Price Target | % Change From Current Price |
---|---|---|
2025 | $1140.00 | Upside of 52.33% |
2026 | $1250.00 | Upside of 56.06% |
2027 | $1520.00 | Upside of 89.77% |
2028 | $1300.00 | Upside of 62.30% |
2029 | $1623.00 | Upside of 102.63% |
2030 | $1850.00 | Upside of 130.97% |
Are you ready for retirement? Planning for retirement can be overwhelming, that’s why it could be a good idea to speak to a fiduciary financial advisor about your goals today.
Start by taking this retirement quiz right here from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes. Smart Asset is now matching over 50,000 people a month.
Click here now to get started.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.